1.High basal metabolic rate/fat-free mass ratio in Japanese elite male athletes can be attributed to body composition
Wakako Tatsuta ; Yukari Yokota ; Akiko Kamei ; Noriyuki Tawara ; Takashi Kawahara ; Motoko Taguchi ; Mitsuru Higuchi
Japanese Journal of Physical Fitness and Sports Medicine 2012;61(4):427-433
The aim of the present study was to evaluate the relation between basal metabolic rate (BMR) and body composition in 29 Japanese elite male athletes (age 25.6±3.7y, height 175.6±7.0cm, body weight 74.7±12.8kg, fat-free mass (FFM) 64.9±9.3kg). The subjects were classified into three groups according to their FFM. There was a significant difference in BMR/FFM between S-group (less than 0.5SD of average FFM) and L-group (more than 0.5SD). The parcentage of RM to body weight in S-group was significantly higher than in L-group. In conclusion, high basal metabolic rate/fat-free mass ratio in Japanese elite male athletes can be attributed to body composition.
2.Effect of enhanced recovery after surgery protocol on recovery after open hepatectomy: a randomized clinical trial
Wataru NAKANISHI ; Shigehito MIYAGI ; Kazuaki TOKODAI ; Atsushi FUJIO ; Kengo SASAKI ; Yoshihiro SHONO ; Michiaki UNNO ; Takashi KAMEI
Annals of Surgical Treatment and Research 2020;99(6):320-328
Purpose:
Enhanced recovery after surgery (ERAS) is beneficial to patients undergoing digestive surgery. However, its efficacy in patients undergoing open hepatectomy remains unclear.
Methods:
Consecutive patients scheduled for open hepatectomy were randomly assigned to undergo either ERAS or conventional postoperative management. The primary endpoint was the amount of time that elapsed before patients were considered medically fit for discharge (MFD) and length of hospital stay (LOHS). Secondary endpoints included morbidity, mortality, the time to first flatus, defecation, first walk, and freedom from infusion. Perioperative serum nutritional markers, insulin resistance, respiratory quotient (RQ), and resting energy expenditure (REE) were also assessed.
Results:
Between August 2014 and March 2017, 57 patients were randomized into 2 groups; ERAS group (n = 29) and conventional management (n = 28). The median MFD was not significantly different between the ERAS and conventional management groups (6.5 vs. 7 days; P = 0.381). Recovery from gastrointestinal paresis was significantly quicker in the ERAS group (1.8 vs. 2.4 days; P = 0.004). There were no significant differences in serum markers, insulin resistance, RQ, and REE.
Conclusion
This trial did not demonstrate greater efficacy of the ERAS protocol following open hepatectomy in terms of the MFD and LOHS. However, the ERAS protocol was associated with better recovery from postoperative gastrointestinal paresis, suggesting that it is useful for patients undergoing open hepatectomy.
3.Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan
Masakazu HATANO ; Ippei TAKEUCHI ; Kanade YAMASHITA ; Aoi MORITA ; Kaori TOZAWA ; Takashi SAKAKIBARA ; Genta HAJITSU ; Manako HANYA ; Shigeki YAMADA ; Nakao IWATA ; Hiroyuki KAMEI
Clinical Psychopharmacology and Neuroscience 2021;19(4):610-617
Objective:
To identify factors affecting adherence to medication, a subjective questionnaire survey was administered to schizophrenia patients regarding the prescribed antipsychotic formulations.
Methods:
We evaluated the patients’ satisfaction and dissatisfaction with prescribed antipsychotic formulations, and patients answered the Drug Attitude Inventory-10 Questionnaire (DAI-10). Inclusion criteria for patients are as follows:age between 20 and 75 years and taking antipsychotic agents containing the same ingredients and formulations, for at least 1 month.
Results:
In total, 301 patients answered the questionnaire survey. Tablets were found to be the most commonly used antipsychotic formulations among schizophrenia patients (n = 174, 57.8%), followed by long-acting injections (LAIs, n = 93, 30.9%). No significant differences in the formulation satisfaction level and DAI-10 scores were observed between all formulations. Formulations, except for LAI, were selected by physicians in more than half of the patients.Patients who answered “Decided by consultation with physicians” had significantly higher satisfaction levels and DAI-10 scores compared to those who answered “Decided by physicians” (4.11 ± 0.77 vs. 3.80 ± 1.00, p = 0.0073 and 6.20 ± 3.51 vs. 4.39 ± 4.56, p < 0.001, respectively). Satisfaction levels moderately correlated with DAI-10 scores (r = 0.48, p < 0.001).
Conclusion
No formulation had a high satisfaction level in all patients, and it is important to be reflect the patients’ individual preferences in pharmacotherapy. Shared decision-making in the selection of the formulations is seen to be useful for improving medication adherence.
4.Successful remission of ulcerative colitis flare-up during pregnancy with adsorptive granulomonocytapheresis plus tacrolimus.
Tomoyoshi SHIBUYA ; Keiichi HAGA ; Masato KAMEI ; Koki OKAHARA ; Shoko ITO ; Masahito TAKAHASHI ; Osamu NOMURA ; Takashi MURAKAMI ; Masae MAKINO ; Tomohiro KODANI ; Dai ISHIKAWA ; Naoto SAKAMOTO ; Taro OSADA ; Tatsuo OGIHARA ; Sumio WATANABE ; Akihito NAGAHARA
Intestinal Research 2018;16(3):484-488
Ulcerative colitis (UC) is 1 of the 2 major phenotypes of chronic inflammatory bowel disease (IBD), which afflicts millions of individuals throughout the world with debilitating symptoms that impair function and quality of life. Further, IBD often affects women during childbearing age. Indeed, UC activity frequently increases during pregnancy, and the medications used to induce remission may adversely affect the health of the mother and the unborn child. We report successful induction of a remission in a UC case who experienced a flare-up in the first trimester of pregnancy. Upon relapse, she was treated with steroids and adsorptive granulomonocytapheresis (GMA) with the Adacolumn plus tacrolimus. This combination therapy induced a stable remission that was maintained during her entire pregnancy. She gave birth to a healthy child at 36 weeks of pregnancy with no maternal or fetal complications. Our experience indicates that GMA, as a non-drug therapeutic intervention with a favorable safety profile, plus tacrolimus might be a relevant treatment option for patients with active IBD during pregnancy. A future study of a large cohort of pregnant patients should strengthen our findings.
Child
;
Cohort Studies
;
Colitis, Ulcerative*
;
Female
;
Humans
;
Inflammatory Bowel Diseases
;
Mothers
;
Parturition
;
Phenotype
;
Pregnancy Trimester, First
;
Pregnancy*
;
Quality of Life
;
Recurrence
;
Steroids
;
Tacrolimus*
;
Ulcer*